Serum Institute of India gets DCGI nod to resume clinical trial of Oxford COVID-19 vaccine

SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.

from News-Economic Times https://ift.tt/2E3eKw3